The independent medical news service
05-12-2018 | Lymphoma | News | Article
Durable response to tisagenlecleucel shown in DLBCL
Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.
19-10-2018 | Oncology | News | Article
Post-induction PET predicts outcome in follicular lymphoma
Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.
17-10-2018 | Oncology | News | Article
Duvelisib offers treatment alternative for patients with CLL/SLL
The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.
28-09-2018 | Oncology | News | Article
In other news: Hematologic cancer focus
This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.
07-09-2018 | Lymphoma | News | Article
Circulating tumor DNA predicts DLBCL outcomes
Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.
27-07-2018 | Oncology | News | Article
In other news: Focus on clinical trial endpoints
This month’s round-up covers three studies evaluating clinical trial endpoints, two focusing on endpoints for programmed cell death protein 1 inhibitor trials and one assessing the surrogacy of progression-free survival in the first-line diffuse large B-cell lymphoma setting. Read on for more details.
IV drip/© zlikovec / Fotolia, Older man taking pill/© seb_ra / Getty Images / iStock (symbolic image with models), Pills_various/© nikesidoroff / fotolia.com, Fausto Castagnetti, USA outline_flag/© Image by Gordon Johnson from Pixabay, Man receiving radiotherapy/© Mediteraneo / Fotolia, Pills in hand/© stock_colors / Getty Images / iStock, Male & female outlines_chalk/© TimArbaev / iStock / Thinkstock, Hisham Mehanna/© Lynda Williams, IV drip_patient's hand/© sippakorn yamkasikorn / iStock / Thinkstock, Elizabeth Phillips, Nilanjan Ghosh, Matthew Wilson, Charles Herbaux, IV drip/© Trsakaoe / stock.adobe.com, Pipette_rack with samples/© science photo / Fotoli, Thomas John, Upset older man/© Willowpix / Getty Images / iStock, Tablet_survey_emojis/© Tero Vesalainen / Getty Images / iStock